Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00153062 · ClinicalTrials.gov registry record · Phase 4
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 20,332
- Enrollment target
NCT00153062 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 20,332 participants.
The verdict
NCT00153062, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20,332 participants
- Enrollment target
Study Summary
The purpose of the trial is to determine if extended-release dipyridamole + aspirin \[Aggrenox, Asasa ntin\] is superior to clopidogrel \[Plavix\], and if telmisartan \[Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan\] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.
Interventions
- DRUG Aggrenox
- DRUG Clopidogrel placebo
- DRUG Micardis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,332 participants |
| Start Date | 2003-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00153062
The ClinicalTrials.gov registry entry for NCT00153062 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20,332 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Aggrenox is the first listed.
NCT00153062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00153062 about?
NCT00153062 is a clinical study titled "PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes". The purpose of the trial is to determine if extended-release dipyridamole + aspirin \[Aggrenox, Asasa ntin\] is superior to clopidogrel \[Plavix\], and if telmisartan \[Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan\] is superior to placebo, in the presence of back...
What is the current status of trial NCT00153062?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20,332 participants. The study started on 2003-08.
What interventions are being tested in trial NCT00153062?
The interventions under investigation include: Aggrenox (DRUG), Clopidogrel placebo (DRUG), Micardis (DRUG).
Who is sponsoring clinical trial NCT00153062?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.